MedTrace Logo

Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe

NCT06408324 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 275

Last updated 2024-05-16

No results posted yet for this study

Summary

The goal of this multicenter, observational, retrospective is to evaluate the standards of use of thrombopoietin receptor agonists (TPO-RA) in adult patients with primary immune thrombocytopenia (ITP), with a particular interest on phase of ITP (defined according to time when diagnosis of ITP is established in the medical records: newly diagnosed, 0-3 months; persistent, 3-12 months, and chronic, \> 12 months), tolerability, safety, posology and remissions, outside controlled clinical trials.

Secondary Objectives:

To analyze the patient characteristics that could affect the choice of thrombopoietin receptor agonist for the treatment of ITP, considering specific clinical aspects (such as previous thromboembolic disease, bleeding, platelet count, surgical procedures, etc.).

To evaluate the degree of adherence to international guidelines related to the use of thrombopoietin receptor agonists in regular clinical practice.

Data will be collected through a retrospective chart review of patients with ITP who started TPO-RA treatment between January 2014 and December 2018.

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Sponsors & Collaborators

  • Fondazione Progetto Ematologia

    collaborator OTHER

  • European Research Consortium on ITP

    lead OTHER

Principal Investigators

  • Maria L. Lozano, M.D. · Hematology and Medical Oncology Dept. Hospital General Universitario José María Morales Meseguer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-24
Primary Completion
2024-04-05
Completion
2024-04-05

Countries

  • France
  • Italy
  • Norway
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06408324 on ClinicalTrials.gov